The Male Contraception drugs in development market research report provides comprehensive information on the therapeutics under development for Male Contraception, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Male Contraception. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Male Contraception - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Male Contraception and features dormant and discontinued products.

GlobalData tracks 11 drugs in development for Male Contraception by ten companies/universities/institutes. The top development phase for Male Contraception is preclinical with six drugs in that stage. The Male Contraception pipeline has eight drugs in development by companies and three by universities/ institutes. Some of the companies in the Male Contraception pipeline products market are: Eunice Kennedy Shriver National Institute of Child Health and Human Development, Population Council and Eppin Pharma.

The key targets in the Male Contraception pipeline products market include Androgen Receptor (Dihydrotestosterone Receptor or Nuclear Receptor Subfamily 3 Group C Member 4 or DHTR or NR3C4 or AR), cAMP Dependent Protein Kinase Catalytic Subunit Alpha (PKACA or PRKACA or EC 2.7.11.11), and Cation Channel Sperm Associated Protein 1 (hCatSper or CATSPER1).

The key mechanisms of action in the Male Contraception pipeline product include Androgen Receptor (Dihydrotestosterone Receptor or Nuclear Receptor Subfamily 3 Group C Member 4 or DHTR or NR3C4 or AR) Agonist with three drugs in Phase II. The Male Contraception pipeline products include three routes of administration with the top ROA being Oral and one key molecule types in the Male Contraception pipeline products market including Small Molecule.

Male Contraception overview

Male contraception is a reduction of the number of fertile sperm ejaculated into the vagina to levels that reliably prevent fertilization. Conception can be prevented by diverting or suppressing sperm output or by inhibiting sperm fertilizing capacity. So far, all male methods depend on mechanical means to reduce female exposure to sperm using either traditional drug and device-free methods (abstinence, withdrawal, or non-vaginal intercourse) or contemporary male methods comprising condoms and vasectomy.

For a complete picture of Male Contraception’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.